Rathbones Group PLC Reduces Stock Position in Zoetis Inc. $ZTS

Rathbones Group PLC cut its holdings in Zoetis Inc. (NYSE:ZTS) by 29.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 375,031 shares of the company’s stock after selling 157,033 shares during the quarter. Rathbones Group PLC owned approximately 0.09% of Zoetis worth $47,186,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC lifted its holdings in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares during the period. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the 4th quarter worth approximately $25,000. Lodestone Wealth Management LLC purchased a new position in shares of Zoetis during the fourth quarter valued at approximately $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the third quarter valued at approximately $31,000. Finally, Holos Integrated Wealth LLC bought a new position in shares of Zoetis during the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. HSBC set a $140.00 target price on shares of Zoetis in a research report on Wednesday, December 10th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Finally, Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Trading Down 0.1%

NYSE:ZTS opened at $117.83 on Monday. The stock has a market cap of $49.74 billion, a price-to-earnings ratio of 19.57, a PEG ratio of 1.80 and a beta of 0.98. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company’s 50 day moving average price is $122.71 and its 200-day moving average price is $127.96. Zoetis Inc. has a 52 week low of $113.29 and a 52 week high of $172.23.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same period in the previous year, the business earned $1.40 EPS. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.